스마트 인슐린 펜 시장은 2024년부터 2031년까지 CAGR 11.2%로 2031년까지 7억 7,650만 달러에 달할 것으로 예상됩니다.
본 보고서는 광범위한 2차 및 1차 조사와 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 억제요인, 도전 과제 및 기회 분석으로 구성되어 있습니다. 스마트 인슐린 펜 시장의 성장은 당뇨병 유병률 증가, 디지털 건강 솔루션에 대한 선호도 증가, 스마트 인슐린 펜의 기술 발전, 약물 자가 투여에 대한 수요 증가, 당뇨병 인식 개선에 대한 전 세계적인 노력에 의해 주도되고 있습니다. 그러나 스마트 인슐린 펜의 높은 비용과 대체품의 낮은 가용성은 이 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
또한, 원격 모니터링 및 원격의료에 대한 수요 증가, 스마트 인슐린 펜 제조업체 간의 제휴 및 협력, 경제 성장, 개인화된 당뇨병 관리 등은 시장 성장의 기회를 창출할 것으로 예상됩니다. 그러나 신흥국의 스마트 인슐린 펜 사용에 대한 이해 부족과 기존 인슐린 전달 기술에 대한 선호도는 스마트 인슐린 펜 시장의 큰 도전 과제입니다.
(참고 : 상위 5개사 SWOT 분석을 제공합니다)
Smart Insulin Pens Market Size, Share, Forecast, & Trends Analysis by Product (Reusable, Disposable Prefilled, Cartridge) Connectivity (Bluetooth, NFC) Compatibility (Blood Glucose Monitor, CGM) Channel (Hospital, Retail, Online)-Global Forecast to 2031
The smart insulin pens market is projected to reach $776.5 million by 2031 at a CAGR of 11.2% from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the smart insulin pens market is driven by the rising incidence of diabetes, growing preference for digital health solutions, technological advancements in smart insulin pens, an increase in demand for drug self-administration, and initiatives worldwide toward diabetes awareness. However, the high cost of smart insulin pens, along with the low availability of alternatives, are restraining the growth of this market.
Furthermore, the rising demand for remote monitoring and telemedicine, partnerships and collaborations among smart insulin pen manufacturers, expanding economies, and personalized diabetes management are expected to generate market growth opportunities. However, a lack of understanding about the use of smart insulin pens in developing nations and a preference for traditional insulin delivery techniques are major challenges in the smart insulin pens market.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the smart insulin pens market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Sanofi S.A. (France), Medtronic plc (Ireland), Emperra GmbH E-Health Technologies (Germany), pendiq GmbH (Germany), Jiangsu Delfu medical device Co., Ltd (China), Tandem Diabetes Care, Inc. (U.S.), Ypsomed AG (Switzerland), and Bigfoot Biomedical, Inc. (U.S.).
Among all products covered in this report, in 2024, the insulin cartridges segment is expected to account for the largest share of 63.3% of the smart insulin pen market. High diabetes incidence worldwide and technological advancements in insulin delivery systems are supporting the segment's largest share. Insulin cartridges offer ease of use and comfort to the patients. These also help in reducing drug wastage and providing accurate insulin dosing.
Among all connectivity covered in this report, in 2024, the Bluetooth connectivity segment is expected to account for the major share of the smart insulin pens market. The largest share is attributed to ease of data sharing, high range of connectivity, its integration with CGM systems, and access to real-time data. These factors offer convenience and flexibility to the user, which results in consumer preference for Bluetooth-connected smart insulin devices over insulin pens.
Among all glucose monitor compatibilities covered in this report, in 2024, the blood glucose monitor (BGM)-compatible pens segment to dominate the smart insulin pens market. The low cost of blood glucose monitors, high accuracy in results, and point-in-time ability to monitor blood glucose levels are the factors attributed to the largest share of the segment. Moreover, technological advancements in the monitors and compatibility with different smart insulin pens also support the segment's large market share.
Among all purchase channels covered in this report, in 2024, the retail pharmacies segment is expected to account for the largest share of 49.2% of the smart insulin pens market. The availability of retail pharmacies in the vicinities, the availability of a diverse range of products, and the chance to inspect the product before making a purchase attract consumers towards retail pharmacies. Moreover, the trustworthiness of pharmacists helps consumers make confident purchase decisions.
An in-depth analysis of the geographical scenario of the smart insulin pens market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Among all the geographies studied in this report, in 2024, North America is expected to account for the largest share of 35% of the smart insulin pens market. The presence of key market players, high healthcare spending, high patient population, and ease of accessibility to technologically advanced devices support the large share of this regional market.
Smart Insulin Pens Market Assessment-By Product
Note: Accessories include data transmitters & injector ports.
Smart Insulin Pens Market Assessment-By Connectivity
Smart Insulin Pens Market Assessment-By Glucose Monitor Compatibility
Smart Insulin Pens Market Assessment-By Purchase Channel
Smart Insulin Pens Market Assessment-By Geography
(Note: SWOT analysis of the top 5 companies will be provided.)